PE Triage Platform from RapidAI Receives FDA 510(k) Clearance
The new artificial intelligence-powered software reportedly helps detect central pulmonary embolism (PE) on computed tomography pulmonary angiogram (CTPA) images and streamlines communication among interventional teams to bolster treatment outcomes.
Could an emerging artificial intelligence (AI)-enabled triage platform facilitate earlier detection and treatment for people who suffer a pulmonary embolism (PE)?
The Rapid PE Triage & Notification product has garnered 510(k) clearance from the Food and Drug Administration (FDA), according to the product’s manufacturer RapidAI.
The AI-enabled platform reportedly offers a variety of key benefits in the diagnosis and treatment of PE.
• Enhanced identification of suspected central PE on computed tomography pulmonary angiogram (CTPA) images
• Real-time notification with previews of CTPA imaging available for review via mobile devices, desktop computers and laptops
• Streamlined communication among interventional teams to facilitate triage of priority cases and timely treatment
“I’m excited to see firsthand how artificial intelligence will transform the way we triage and manage PE, a historically complicated process involving a diverse care team,” noted Jimmy Kerrigan, MD, FSCAI, FACC, RPVI, an interventional cardiologist affiliated with Ascension Saint Thomas Heart at multiple locations in Tennessee. “After seeing what RapidAI technology has done for stroke, I’m optimistic about about its potential to optimize our care for patients and to hopefully improve patient outcomes.”
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
